Anti-Human CD307e (FcRL5) – Purified

Anti-Human CD307e (FcRL5) – Purified

Product No.: I-1221

- -
- -
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
CD307e, CD307, BXMAS1, FCRH5, Fc receptor-like protein 5, IRTA2
IgG2a κ

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Host Species
Cells transfected with Human FcRL5.
Product Concentration
0.5 mg/ml
This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
This purified antibody is stable when stored at 2-8°C. Do not freeze.
Country of Origin
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for this CD307e antibody for staining cells in flow cytometry is ≤ 0.125 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Additional Applications Reported In Literature ?
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.


Clone 50946 recognizes human FcRL5 within the first 3 Ig domains. Clone 50946 does not cross-react with FcRL4.
FcRL5 antibody, 509F6, recognizes Fc receptor-like 5 (FcRL5), also known as immunoglobulin superfamily receptor translocation associated 2 (IRTA2), Fc receptor homolog 5 (FcRH5), and BXMAS1. FcRL5 is a 106 kDa type I transmembrane glycoprotein containing 9 Ig-like extracellular domains, a cytoplasmic ITAM-like consensus sequence, and two cytoplasmic ITIM-like sequences1. FcRL5 is found on most mature B cells, with the highest levels on naive and memory B cells and plasma cells1,2. FcRL5 is an IgG receptor and binds to all IgG isotypes3, resulting in the inhibition of BCR signaling through the recruitment of SH2 domain-containing tyrosine phosphatase 1 (SHP-1) after tyrosine phosphorylation of its two ITIMs4. B cell malignancies, including multiple myeloma, chronic lymphocytic leukemia, mantle cell lymphoma, and hairy cell leukemia, often exhibit aberrant FCRL5 expression, indicating FcRL5 as a potential biomarker or therapeutic target5-7.
Antigen Distribution
FcRL5 is expressed on mature B cells and plasma cells.

Antigen Details

Aggregated IgG
NCBI Gene Bank ID

References & Citations

1. M. D. Cooper., et al. (2001). Proc. Natl. Acad. Sci. USA 98: 9772–9777
2. Koeppen H., et al. (2006) Int Immunol. 18:1363-1373
3. Colonna M., et al. (2012) J Immunol. 188(10):4741-5
4. M. D. Cooper., et al (2007) Proc. Natl. Acad. Sci. USA 104: 9770–9775
5. Dalla-Favera R., et al. (2001) Immunity. 14(3):277-89
6. Pastan I., et al. (2007) Leukemia. 21(1):169-74
7. Nagata S., et al. (2005) Clin Cancer Res. 11(1):87-96
Flow Cytometry
Immunoprecipitation Protocol

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.